Wedbush analyst David Nierengarten reiterated an Outperform rating on bluebird bio (NASDAQ: BLUE) following today's ASH abstract update but cut ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE